China: Life Sciences, Biotechnology & Nanotechnology

China's National Intellectual Property Administration has launched a comprehensive 2026 nationwide patent survey targeting approximately 13,000 patent holders and 40,000 valid patents across 27 provinces. The survey will examine patent creation, protection, utilization, commercialization rates, infringement cases, high-value compensation, industry-academia collaboration, and overseas patent activities to inform intellectual property policy development.

金诚同达律师事务所发布《生命健康法律期刊》第二期，汇集2026年4-6月生命健康领域的政策动态、产业资讯、科技突破、热词解析及专业法律观点。&

China's National Medical Products Administration has officially implemented new drug trial data protection measures, establishing a comprehensive framework that grants varying protection periods based on innovation levels.

The SPC pointed out in an administrative appeal that, for product claims containing a subject name with usage limitation, the usage limitation must be considered when determining the scope of protection.

外資系企業による中国での研究開発投資が拡大している。今年1〜2月に新設された外資系企業は8631社に上り、前年同期比で14％増加した...

Precision medicine is rapidly transforming the global healthcare landscape, providing more effective therapies and better patient outcomes through targeted solutions.

A recent criminal judgment published by the Gao'an People's Court in Jiangxi province (江西省高安市人民法院) in June 2025 has drawn public attention to Jiangxi Baishen Pharmaceutical Co.

Earlier this year, the Commission relied for the first time on the EU's International Procurement Instrument in order to take measures against China for its failure to ensure reciprocal access to public...

2022年5月9日，国家药监局发布《药品管理法实施条例（修订草案征求意见稿）》（简称"《征求意见稿》"），向社会公开征求意见，征求意见反馈截止